查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081983

心臟衰竭治療市場：2026-2032年全球市場預測（依藥物類別、心臟衰竭類型、給藥途徑、作用機制、最終用戶和通路分類）

Heart Failure Therapeutics Market by Drug Class, Heart Failure Type, Mode Of Administration, Mechanism of Action, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心臟衰竭治療市場規模將成長至 602.3 億美元，複合年成長率為 10.94%。

主要市場統計數據
基準年 2025 291億美元
預計年份：2026年 316.9億美元
預測年份 2032 602.3億美元
複合年成長率 (%) 10.94%

心臟衰竭藥物市場概覽

世界衛生組織（WHO）的數據顯示，全球有超過6,400萬人患有心臟衰竭，心血管疾病每年導致約1,790萬人死亡，因此心臟衰竭藥物治療仍是心血管疾病治療的核心。心臟衰竭的治療模式正從暫時控制症狀轉向以指引為基礎的藥物治療。無論射血分數降低、輕度降低或正常，此方法都能降低死亡率、減少住院次數、改善功能狀態並延緩疾病進展。

心臟衰竭治療領域發生的變革性變化

心臟衰竭的治療格局正因低心率輸出量心臟衰竭「四支柱」療法的迅速推廣、SGLT2抑制劑在所有心率輸出量類別中的廣泛應用，以及診斷或出院後早期啟動聯合治療而發生重塑。美國心臟協會 (AHA)、美國心臟病學會 (ACC)、美國心臟衰竭協會 (HFSA) 和歐洲心臟病學會 (ESC) 的權威指南強調基於實證醫學的快速藥物最佳化，而非逐步增加劑量，這反映了臨床試驗的結果，即及時治療可降低心血管死亡和心臟衰竭住院率。

人工智慧（AI）的累積影響

人工智慧（AI）正逐漸超越治療手段，成為心臟衰竭管理中一種實用的輔助工具。檢驗的AI工具正被用於心電圖解讀、心臟超音波圖工作流程、風險分層、患者識別、藥物依從性支持，以及利用電子健康記錄、影像、檢驗結果、穿戴式設備和遠端監測數據預測臨床惡化。

心臟衰竭治療的關鍵區域見解

亞太地區是心臟衰竭治療領域一個極其活躍的區域，其發展動力主要來自不斷成長的老齡人口、日益普遍的糖尿病、都市化以及中國、印度、日本、澳大利亞和韓國不斷完善的循環系統醫療基礎設施。北美地區則繼續保持創新和應用的重要中心地位，這得益於AHA/ACC/HFSA指南的實施、專業的心臟衰竭項目、高密度的臨床試驗、先進的診斷技術、相對完善的品牌藥物醫保報銷機制、門診治療模式以及數位化醫療的整合。

策略市場定位的關鍵群體洞察

在東協市場，由於各國政府擴大醫院網路並加強非傳染性疾病控制項目，心臟衰竭治療的重要性日益凸顯。然而，取得新型心臟衰竭藥物的機會因保險報銷機制、公共採購以及都市區醫療衛生體系的不同而有所差異。海灣合作理事會（GCC）地區具有重要的戰略意義，因為該地區糖尿病、高血壓、肥胖和慢性腎臟病的高發病率持續推高了對心血管代謝疾病和心臟衰竭治療的需求。醫療衛生現代化計畫、專科醫療中心以及對數位醫療基礎設施的投資為此提供了支持。

對主要心臟衰竭市場關鍵國家的洞察

美國在心臟衰竭治療市場擁有最大的商業性影響力，這得益於其高疾病負擔、高度專業化的醫療保健體系、廣泛的臨床試驗參與以及基於指南的藥物療法的快速實施。加拿大採用類似的臨床標準，但其特點是擁有更強大的集中式成本效益評估體係以及省級醫保報銷制度的影響。墨西哥和巴西是重要的拉丁美洲市場，公共醫療保健的可及性、私人保險的普及率、本地採購以及專科醫生的可及性都會影響先進心臟衰竭治療藥物的分配。

為行業領導者提供的實用建議

行業領導者應優先考慮能夠顯著降低住院率、心血管死亡率、症狀負擔和整體醫療成本的療法和計畫。產品系列策略必須與基於指南的藥物治療一致，支持快速劑量調整，並解決常見的合併症，例如慢性腎臟病、糖尿病、缺鐵性貧血、高血壓、心房顫動和肥胖症。

調查方法

本調查方法基於二手資料研究，採用經核實的公共和科學資源，包括全球衛生組織、循環系統指南、法規核准文件、同行檢驗的臨床試驗、衛生技術評估（HTA）資訊來源、流行病學資料庫和疾病負擔出版物。研究優先資訊來源世界衛生組織（WHO）、美國心臟協會/美國心臟病學會/美國心臟衰竭協會（AHA/ACC/HFSA）、歐洲心臟病學會（ESC）、各國監管機構以及評估死亡率、住院率、安全性和生活品質（QOL）結局的開創性隨機心臟衰竭試驗的證據。

結論

心臟衰竭治療正進入一個更注重療效的階段，其特徵是早期診斷、快速啟動聯合治療、更廣泛地使用SGLT2抑制劑、加強合併症管理，以及利用數位技術和人工智慧進一步整合醫療服務。在這種競爭激烈的環境下，那些能夠提高生存率、降低住院率、簡化治療路徑、改善用藥依從性並在真實世界心臟衰竭患者群體中展現價值的療法正受到評估。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章心臟衰竭治療市場：依藥物類別分類

  • ACE抑制劑
  • 血管收縮素II受體拮抗劑
  • BETA阻斷劑
  • 利尿劑
  • 鹽皮質激素受體拮抗劑
  • SGLT2抑制劑

第8章心臟衰竭治療市場：依心臟衰竭類型分類

  • 保留射血分數
  • 射血分數降低型
  • 射血分數（EF）輕度降低的心臟衰竭

第9章：心臟衰竭治療市場：依給藥途徑分類

  • 靜脈
  • 口服

第10章：心臟衰竭治療市場：依作用機制分類

  • 神經激素調節
  • 血管舒張
  • 增強收縮力的效果
  • 代謝調控

第11章心臟衰竭治療市場：依最終用戶分類

  • 診所
  • 居家醫療
  • 醫院

第12章心臟衰竭藥物市場：依分銷管道分類

  • 離線
    • 醫院藥房
    • 零售藥房
  • 線上

第13章心臟衰竭治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章心臟衰竭治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章心臟衰竭治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Abiomed, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioCardia, Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • CVRx, Inc.
  • Cytokinetics, Inc.
  • Edwards Lifesciences Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Les Laboratoires Servier
  • Medtronic plc
  • Merck & Co., Inc.
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals, Inc.
  • Renova Therapeutics, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-430D42AA0D2E

The Heart Failure Therapeutics Market is projected to grow by USD 60.23 billion at a CAGR of 10.94% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 29.10 billion
Estimated Year [2026] USD 31.69 billion
Forecast Year [2032] USD 60.23 billion
CAGR (%) 10.94%

Heart Failure Therapeutics Market Introduction

Heart failure therapeutics remain central to cardiovascular care because heart failure affects more than 64 million people worldwide, while cardiovascular diseases cause an estimated 17.9 million deaths each year, according to the World Health Organization. The heart failure treatment landscape is shifting from episodic symptom control toward guideline-directed medical therapy that lowers mortality, reduces hospitalization, improves functional status, and slows disease progression across reduced, mildly reduced, and preserved ejection fraction.

Demand for evidence-based heart failure drugs is reinforced by aging populations, diabetes, obesity, hypertension, chronic kidney disease, and improved survival after myocardial infarction. Clinicians are increasingly using angiotensin receptor-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 inhibitors, diuretics, iron repletion, and device-enabled care in integrated pathways designed to improve outcomes and support long-term disease management.

Transformative Shifts in the Heart Failure Landscape

The heart failure therapeutics landscape is being reshaped by the rapid adoption of four-pillar treatment for heart failure with reduced ejection fraction, wider use of SGLT2 inhibitors across ejection-fraction categories, and earlier initiation of combination therapy after diagnosis or hospital discharge. Major guidelines from the AHA, ACC, HFSA, and ESC emphasize faster optimization of evidence-based medicines rather than slow sequential escalation, reflecting clinical trial evidence that timely treatment reduces cardiovascular death and heart failure hospitalization.

Commercial strategy is also changing. Payers increasingly evaluate heart failure therapies by their ability to reduce hospital admissions, improve quality of life, support outpatient management, and lower avoidable acute-care use. At the same time, patent expirations, generic availability, fixed-dose combinations, remote patient monitoring, and multidisciplinary care models are changing access, pricing, adherence, and differentiation across the heart failure drug market.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical enabler in heart failure therapeutics rather than a standalone treatment. Validated AI tools are being applied to electrocardiogram interpretation, echocardiography workflows, risk stratification, patient identification, medication adherence support, and prediction of clinical decompensation using electronic health records, imaging, laboratory results, wearable devices, and remote monitoring data.

The cumulative impact is strongest where AI improves earlier diagnosis, therapy titration, clinical trial recruitment, population health management, and pharmacovigilance. However, adoption depends on transparent validation, demographic fairness, cybersecurity, clinician oversight, and regulatory alignment. For drug developers and healthcare decision-makers, AI-enabled real-world evidence can strengthen market access dossiers, identify underdiagnosed patients, and support selection of patients most likely to benefit from specific heart failure therapies.

Key Regional Insights Across Heart Failure Therapeutics

Asia-Pacific is a highly dynamic heart failure therapeutics region due to large aging populations, rising diabetes prevalence, urbanization, and expanding cardiology infrastructure across China, India, Japan, Australia, and South Korea. North America remains a leading innovation and adoption hub, supported by AHA/ACC/HFSA guideline implementation, specialist heart failure programs, clinical trial density, advanced diagnostics, and comparatively strong reimbursement for branded therapies, outpatient care models, and digital health integration.

Latin America shows increasing demand for heart failure treatment but faces uneven access to advanced medicines, diagnostics, and specialist services, with Brazil and Mexico acting as key regional anchors. Europe benefits from ESC-led standardization, national health technology assessment systems, broad use of evidence-based therapy, and structured pharmacovigilance, although cost-effectiveness scrutiny is significant. The Middle East is expanding cardiovascular investment as diabetes, hypertension, and obesity burden rises, while Africa remains underpenetrated, with affordability, diagnosis rates, workforce capacity, and supply continuity shaping therapeutic uptake.

Key Group Insights for Strategic Market Positioning

ASEAN markets are gaining relevance as hospital networks expand and governments strengthen noncommunicable disease programs, though access to newer heart failure medicines varies by reimbursement, public procurement, and urban-rural capacity. The GCC is strategically important because high rates of diabetes, hypertension, obesity, and chronic kidney disease create sustained demand for cardiometabolic and heart failure care, supported by healthcare modernization programs, specialty centers, and investment in digital health infrastructure.

The European Union provides regulatory scale, pharmacovigilance infrastructure, and health technology assessment-driven pricing discipline, making clinical value and budget impact central to access. BRICS countries combine large patient pools with rising domestic manufacturing, expanding insurance coverage, and cost-sensitive procurement, making affordability, local evidence, and supply reliability essential. G7 markets lead in clinical innovation, premium therapy adoption, and real-world evidence generation. NATO members, while not a healthcare bloc, overlap with major high-income markets where supply-chain resilience, essential medicines security, and health-system readiness are increasingly strategic priorities.

Key Country Insights in Major Heart Failure Markets

The United States is the most commercially influential heart failure therapeutics market, supported by high disease burden, advanced specialty care, broad clinical trial participation, and rapid incorporation of guideline-directed medical therapy; Canada follows similar clinical standards with stronger centralized cost-effectiveness review and provincial reimbursement influence. Mexico and Brazil are important Latin American markets where public access, private insurance penetration, local procurement, and specialist availability determine uptake of advanced heart failure medicines.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature cardiology systems with pricing oversight, national reimbursement rules, and guideline-based care pathways, while Russia presents a large patient base with access, procurement, and geopolitical constraints. China and India drive Asia-Pacific patient volume, supported by expanding diagnosis, domestic manufacturing, hospital capacity, and policy attention to chronic disease management. Japan, Australia, and South Korea are advanced markets with strong regulatory standards, aging populations, high-quality cardiovascular care, and growing interest in integrated drug-device-digital heart failure management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize therapies and programs that demonstrably reduce hospitalization, cardiovascular mortality, symptom burden, and total cost of care. Portfolio strategies should align with guideline-directed medical therapy, support rapid titration, and address common comorbidities such as chronic kidney disease, diabetes, iron deficiency, hypertension, atrial fibrillation, and obesity.

Manufacturers should expand real-world evidence, pursue inclusive clinical trials, strengthen payer-ready economic models, and invest in patient support that improves treatment persistence and adherence. Regional strategies must balance premium innovation with affordability through tiered pricing, local partnerships, supply security, physician education, and care pathway support for primary care and cardiology teams. AI-enabled identification, remote monitoring integration, decentralized follow-up, and outcomes-based contracting can further improve differentiation in heart failure therapeutics.

Research Methodology

The research methodology is built on secondary research from verified public and scientific sources, including global health agencies, cardiology guidelines, regulatory labels, peer-reviewed clinical trials, health technology assessment frameworks, epidemiology databases, and disease burden publications. Priority was given to evidence from the World Health Organization, AHA/ACC/HFSA, ESC, national regulatory authorities, and landmark randomized heart failure trials evaluating mortality, hospitalization, safety, and quality-of-life outcomes.

Insights were triangulated across disease burden, treatment standards, regulatory status, reimbursement dynamics, clinical adoption, access barriers, comorbidity patterns, and regional healthcare capacity. The analysis avoids unsupported market-size claims and focuses on evidence-backed therapeutic, geographic, and strategic signals relevant to heart failure drug developers, investors, payers, providers, and healthcare decision-makers.

Conclusion

Heart failure therapeutics are entering a more outcomes-driven phase defined by earlier diagnosis, faster initiation of combination therapy, broader SGLT2 inhibitor use, stronger comorbidity management, and deeper integration of digital and AI-enabled care. The competitive landscape rewards therapies that improve survival, reduce hospitalization, simplify care pathways, enhance adherence, and prove value in real-world heart failure populations.

Growth opportunities are strongest where clinical innovation is paired with access strategy and implementation support. Organizations that combine robust evidence, regional affordability, payer engagement, supply reliability, and technology-enabled patient management will be best positioned to meet rising demand across mature and emerging heart failure therapeutics markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Heart Failure Therapeutics Market, by Drug Class

  • 7.1. ACE Inhibitors
  • 7.2. Angiotensin II Receptor Blockers
  • 7.3. Beta Blockers
  • 7.4. Diuretics
  • 7.5. Mineralocorticoid Receptor Antagonists
  • 7.6. SGLT2 Inhibitors

8. Heart Failure Therapeutics Market, by Heart Failure Type

  • 8.1. Preserved Ejection Fraction
  • 8.2. Reduced Ejection Fraction
  • 8.3. Heart Failure with Mildly Reduced EF

9. Heart Failure Therapeutics Market, by Mode Of Administration

  • 9.1. Intravenous
  • 9.2. Oral

10. Heart Failure Therapeutics Market, by Mechanism of Action

  • 10.1. Neurohormonal Modulation
  • 10.2. Vasodilation
  • 10.3. Positive Inotropy
  • 10.4. Metabolic Modulation

11. Heart Failure Therapeutics Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Heart Failure Therapeutics Market, by Distribution Channel

  • 12.1. Offline
    • 12.1.1. Hospital Pharmacies
    • 12.1.2. Retail Pharmacies
  • 12.2. Online

13. Heart Failure Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Heart Failure Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Heart Failure Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Abiomed, Inc.
  • 17.3. Amgen Inc.
  • 17.4. AstraZeneca PLC
  • 17.5. Bayer AG
  • 17.6. BioCardia, Inc.
  • 17.7. Boehringer Ingelheim International GmbH
  • 17.8. Boston Scientific Corporation
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. CVRx, Inc.
  • 17.11. Cytokinetics, Inc.
  • 17.12. Edwards Lifesciences Corporation
  • 17.13. Eli Lilly and Company
  • 17.14. GlaxoSmithKline plc
  • 17.15. Hikma Pharmaceuticals PLC
  • 17.16. Johnson & Johnson Services, Inc.
  • 17.17. Les Laboratoires Servier
  • 17.18. Medtronic plc
  • 17.19. Merck & Co., Inc.
  • 17.20. Novartis AG
  • 17.21. Orion Corporation
  • 17.22. Pfizer Inc.
  • 17.23. PhaseBio Pharmaceuticals, Inc.
  • 17.24. Renova Therapeutics, Inc.
  • 17.25. Sanofi S.A.
  • 17.26. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANGIOTENSIN II RECEPTOR BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANGIOTENSIN II RECEPTOR BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANGIOTENSIN II RECEPTOR BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BETA BLOCKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BETA BLOCKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BETA BLOCKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIURETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIURETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIURETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINERALOCORTICOID RECEPTOR ANTAGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MINERALOCORTICOID RECEPTOR ANTAGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINERALOCORTICOID RECEPTOR ANTAGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SGLT2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PRESERVED EJECTION FRACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRESERVED EJECTION FRACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PRESERVED EJECTION FRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL REDUCED EJECTION FRACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL REDUCED EJECTION FRACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL REDUCED EJECTION FRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE WITH MILDLY REDUCED EF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE WITH MILDLY REDUCED EF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE WITH MILDLY REDUCED EF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROHORMONAL MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROHORMONAL MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROHORMONAL MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VASODILATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASODILATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VASODILATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POSITIVE INOTROPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POSITIVE INOTROPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POSITIVE INOTROPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL METABOLIC MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL METABOLIC MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL METABOLIC MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 137. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. GCC HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. G7 HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 164. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. NATO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 181. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 189. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 197. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 213. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 221. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 229. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 237. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 245. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 261. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 269. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 277. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 285. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART FAILURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)